Indacrinone

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 525278

CAS#: 57296-63-6

Description: Indacrinone is a loop diuretic. It can be used in patients of gout with hypertension as an antihypertensive because it decreases reabsorption of uric acid.

Chemical Structure

img
Indacrinone
CAS# 57296-63-6
Instruction

Theoretical Analysis

MedKoo Cat#: 525278
Name: Indacrinone
CAS#: 57296-63-6
Chemical Formula: C18H14Cl2O4
Exact Mass: 364.03
Molecular Weight: 365.210
Elemental Analysis: C, 59.20; H, 3.86; Cl, 19.42; O, 17.52

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 56049-88-8  

Synonym: Indacrinone; Indacrinone; Indacrinonum; MK 196; MK-196; Acidum indacrinicum;

IUPAC/Chemical Name: Acetic acid, ((2,3-dihydro-6,7-dichloro-2-methyl-1-oxo-2-phenyl-1H-inden-5-yl)oxy)-, (+-)-

InChi Key: PRKWVSHZYDOZLP-UHFFFAOYSA-N

InChi Code: InChI=1S/C18H14Cl2O4/c1-18(11-5-3-2-4-6-11)8-10-7-12(24-9-13(21)22)15(19)16(20)14(10)17(18)23/h2-7H,8-9H2,1H3,(H,21,22)

SMILES Code: O=C(O)COC1=CC2=C(C(C(C3=CC=CC=C3)(C)C2)=O)C(Cl)=C1Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 365.21 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Rybak LP, Whitworth C, Morris C, Scott V, Kanno H. Cochlear effects of indacrinone are not altered by penicillin. Hear Res. 1995 May;85(1-2):122-6. PubMed PMID: 7559168.

2: Beaujean V, Crabbé J. Conductive chloride flux across amphibian skin: inhibition by indacrinone and cobalt ion. Biochim Biophys Acta. 1992 Feb 17;1104(1):174-8. PubMed PMID: 1550845.

3: Takagi S, Takayama S, Onodera T. Hepatotoxicity of DR-3438, tienilic acid, indacrinone and furosemide studied in vitro. Toxicol Lett. 1991 Mar;55(3):287-93. PubMed PMID: 2003271.

4: Hanna GM, Lau-Cam CA. Determination of the optical purity of indacrinone by proton nuclear magnetic resonance spectroscopy using chiral lanthanide chelates. J Pharm Biomed Anal. 1989;7(8):919-28. PubMed PMID: 2562290.

5: Rybak LP, Whitworth C. Ototoxicity of indacrinone is stereospecific. Hear Res. 1987 Dec;31(2):169-74. PubMed PMID: 3446673.

6: Vyas KP, Hichens M, Mulcahy WS, Hand EL. Radioimmunoassays for the enantiomeric components of indacrinone and their phenolic metabolites. J Immunoassay. 1987;8(2-3):179-201. PubMed PMID: 3624493.

7: Dürr JE, Larsen EH. Indacrinone (MK-196)--a specific inhibitor of the voltage-dependent Cl- permeability in toad skin. Acta Physiol Scand. 1986 Jun;127(2):145-53. PubMed PMID: 3088914.

8: Hatzis A, Rothchild R. Optical purity determination and (1)H-NMR spectral simplification with lanthanide shift reagents - VIII. An indacrinone precursor, 6,7-dichloro-5-methoxy-2-methyl-2-phenyl-1-indanone. J Pharm Biomed Anal. 1986;4(4):443-9. PubMed PMID: 16867580.

9: Nagel W, Beauwens R, Crabbé J. Opposite effects of indacrinone (MK-196) on sodium and chloride conductance of amphibian skin. Pflugers Arch. 1985 Apr;403(4):337-43. PubMed PMID: 3925431.

10: Jain AK, Michael R, Ryan JR, McMahon FG. Antihypertensive and biochemical effects of indacrinone enantiomers. Pharmacotherapy. 1984 Sep-Oct;4(5):278-83. PubMed PMID: 6504709.

11: Vlasses PH, Rotmensch HH, Swanson BN, Irvin JD, Johnson CL, Ferguson RK. Indacrinone: natriuretic and uricosuric effects of various ratios of its enantiomers in healthy men. Pharmacotherapy. 1984 Sep-Oct;4(5):272-7. PubMed PMID: 6504708.

12: Field MJ, Fowler N, Giebisch GH. Effects of enantiomers of indacrinone (MK-196) on cation transport by the loop of Henle and distal tubule studied by microperfusion in vivo. J Pharmacol Exp Ther. 1984 Jul;230(1):62-8. PubMed PMID: 6747832.

13: Brooks BA, Lant AF, McNabb WR, Noormohamed FH. Renal actions of a uricosuric diuretic, racemic indacrinone, in man: comparison with ethacrynic acid and hydrochlorothiazide. Br J Clin Pharmacol. 1984 May;17(5):497-512. PubMed PMID: 6428442; PubMed Central PMCID: PMC1463457.

14: Brooks BA, Lant AF, McNabb WR, Noormohamed FH. Stereo-specificity of diuretic receptors in the nephron: a study of the enantiomers of indacrinone (MK-196) in man. Ren Physiol. 1984;7(5):304-10. PubMed PMID: 6484299.

15: Blaine EH, Fanelli GM Jr, Irvin JD, Tobert JA, Davies RO. Enantiomers of indacrinone: a new approach to producing an isouricemic diuretic. Clin Exp Hypertens A. 1982;4(1-2):161-76. PubMed PMID: 7074983.

16: Zacchei AG, Dobrinska MR, Wishousky TI, Kwan KC, White SD. Stereoselectivity in the disposition and metabolism of the uricosuric-diuretic agent, indacrinone, in Rhesus monkeys. Drug Metab Dispos. 1982 Jan-Feb;10(1):20-7. PubMed PMID: 6124378.

17: Robertson RT, Minsker DH, Bokelman DL, Durand G, Conquet P. Potassium loss as a causative factor for skeletal malformations in rats produced by indacrinone: a new investigational loop diuretic. Toxicol Appl Pharmacol. 1981 Aug;60(1):142-50. PubMed PMID: 7281172.

18: Vlasses PH, Irvin JD, Huber PB, Lee RB, Ferguson RK, Schrogie JJ, Zacchei AG, Davies RO, Abrams WB. Pharmacology of enantiomers and (-) p-OH metabolite of indacrinone. Clin Pharmacol Ther. 1981 Jun;29(6):798-807. PubMed PMID: 7226712.

19: Tobert JA, Cirillo VJ, Hitzenberger G, James I, Pryor J, Cook T, Buntinx A, Holmes IB, Lutterbeck PM. Enhancement of uricosuric properties of indacrinone by manipulation of the enantiomer ratio. Clin Pharmacol Ther. 1981 Mar;29(3):344-50. PubMed PMID: 7471605.

20: Brooks BA, Blair EM, Finch R, Lant AF. Studies on the mechanism and characteristics of action of a uricosuric diuretic, indacrinone (MK-196). Br J Clin Pharmacol. 1980 Sep;10(3):249-58. PubMed PMID: 7437242; PubMed Central PMCID: PMC1430055. 6